Determination of free insulin-like growth factor-I in human serum: comparison of ultrafiltration and direct immunoradiometric assay.

Two fundamentally different methods are currently used for the determination of free insulin-like growth factor-I (IGF-I): ultrafiltration by centrifugation (UF) and direct immunoradiometric assay (IRMA). The aim was to evaluate a commercial IRMA (DSL, Webster, TX, USA) and to compare it with UF. In the IRMA it is recommended that samples be incubated for 2 h at 5;C. When comparing samples (n = 8) incubated for 1 and 2 h, levels increased by 27 +/- 5% (P< 0.0001). When incubating samples at 22;C instead of 5;C, levels increased by 192 +/- 32% (P< 0.0001). Addition of IGF-binding protein-1 (IGFBP-1) to normal sera (n = 6) dose-dependently decreased ultrafiltered free IGF-I only (P< 0.0007). Similarly, UF was more sensitive than IRMA to addition of IGFBP-2 (P< 0.05). In healthy subjects (n = 35) IRMA yielded 20% higher levels than UF (1.09 +/- 0.09 vs 0.91 +/- 0.12 microg/L; P< 0.0001). IRMA and UF yielded similar results in healthy subjects treated with IGF-I (n = 5) or growth hormone (n = 7) and in acromegalic patients (n = 6) before and after somatostatin analogue treatment. However, marked differences were observed in conditions with elevated IGFBP-1 and -2. In type-1 diabetics (n = 23) ultrafiltered free IGF-I was more reduced than IRMA free IGF-I (38 +/- 9 vs 76 +/- 7% of matched controls (n = 13); P< 0.0001). In patients with chronic renal failure (n = 25), IRMA free IGF-I was identical to control levels (n = 13), whereas ultrafiltered free IGF-I was decreased by 51 +/- 7% (P< 0.0001). Similarly, women with anorexia nervosa (n = 9) studied before and after weight gain showed significant changes in ultrafiltered free IGF-I only (P< 0.03). In conclusion, IRMA was not very robust with respect to variations in sample incubation and this may bias results. IRMA generally yielded higher levels than UF, in accordance with the knowledge that IRMA measures free plus readily dissociable IGF-I. IRMA was less affected than UF by added IGFBP-1 and -2, and reductions in free IGF-I were better revealed by UF than IRMA.

[1]  H. Orskov,et al.  Serum free insulin-like growth factor-I in growth hormone-deficient adults before and after growth hormone replacement. , 1997, European journal of endocrinology.

[2]  J. Argente,et al.  Multiple endocrine abnormalities of the growth hormone and insulin-like growth factor axis in patients with anorexia nervosa: effect of short- and long-term weight recuperation. , 1997, The Journal of clinical endocrinology and metabolism.

[3]  R. Ekins.  Measurement of free hormones in blood. , 1990, Endocrine reviews.

[4]  H. Orskov,et al.  Free and total insulin-like growth factors and insulin-like growth factor binding proteins during 14 days of growth hormone administration in healthy adults. , 1996, European journal of endocrinology.

[5]  D. Powell,et al.  Kinetics of insulin-like growth factor (IGF) and IGF-binding protein responses to a single dose of growth hormone. , 1997, The Journal of clinical endocrinology and metabolism.

[6]  H. Orskov,et al.  Ultrafiltration method for direct radioimmunoassay measurement of free thyroxine and free tri-iodothyronine in serum. , 1986, Scandinavian journal of clinical and laboratory investigation.

[7]  Y. Song,et al.  Effect of obesity on total and free insulin-like growth factor (IGF)-1, and their relationship to IGF-binding protein (BP)-1, IGFBP-2, IGFBP-3, insulin, and growth hormone , 1997, International Journal of Obesity.

[8]  Y. Hasegawa,et al.  Measurement of free insulin-like growth factor-I using immunoradiometric assay. , 1994, Journal of immunoassay.

[9]  K. Michaelsen,et al.  Free insulin-like growth factor I serum levels in 1430 healthy children and adults, and its diagnostic value in patients suspected of growth hormone deficiency. , 1997, The Journal of clinical endocrinology and metabolism.

[10]  J. Frystyk,et al.  Free insulin‐like growth factors (IGF‐I and IGF‐II) in human serum , 1994, FEBS letters.

[11]  M. Ranke,et al.  A specific radioimmunoassay for insulin-like growth factor II: the interference of IGF binding proteins can be blocked by excess IGF-I. , 1988, Acta endocrinologica.

[12]  H. Orskov,et al.  Free insulin-like growth factors in human obesity. , 1995, Metabolism: clinical and experimental.

[13]  N. Skakkebaek,et al.  Serum insulin-like growth factor-I in 1030 healthy children, adolescents, and adults: relation to age, sex, stage of puberty, testicular size, and body mass index. , 1994, The Journal of clinical endocrinology and metabolism.

[14]  N. Skakkebæk,et al.  Serum concentrations of free and total insulin‐like growth factor‐I, IGF binding proteins ‐1 and‐3 and IGFBP‐3 protease activity in boys with normal or precocious puberty , 1996, Clinical endocrinology.

[15]  K. Takano,et al.  Measurement of free form of insulin-like growth factor I in human plasma. , 1991, Growth regulation.

[16]  C Hagen,et al.  Low serum levels of free and total insulin-like growth factor I (IGF-I) in patients with anorexia nervosa are not associated with increased IGF-binding protein-3 proteolysis. , 1999, The Journal of clinical endocrinology and metabolism.

[17]  S. Lamberts,et al.  Free and total insulin-like growth factor I (IGF-I), IGF-binding protein-1 (IGFBP-1), and IGFBP-3 and their relationships to the presence of diabetic retinopathy and glomerular hyperfiltration in insulin-dependent diabetes mellitus. , 1997, The Journal of clinical endocrinology and metabolism.

[18]  C. Lang,et al.  Growth Hormone Treatment in Growth Retarded Children with End Stage Renal Failure: Effect on Free/Dissociable IGF-I Levels , 1997, Journal of pediatric endocrinology & metabolism : JPEM.

[19]  A. Hoffman,et al.  Pharmacokinetics of insulin-like growth factor-1 in advanced chronic renal failure. , 1996, Kidney international.

[20]  H. Orskov,et al.  Serum-free insulin-like growth factor I correlates with clearance in patients with chronic renal failure. , 1999, Kidney international.

[21]  E. Froesch,et al.  Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. , 1987, The New England journal of medicine.

[22]  M. Binoux,et al.  A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. , 1996, Endocrinology.

[23]  K. Alberti,et al.  A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. , 1993, The Journal of clinical investigation.

[24]  H. Orskov,et al.  Non-competitive time-resolved immunofluorometric assays for determination of human insulin-like growth factor I and II. , 1995, Growth regulation.

[25]  H. Orskov,et al.  The pharmacokinetics of free insulin-like growth factor-I in healthy subjects. , 1999, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[26]  Pols,et al.  Serum free IGF‐I, total IGF‐I, IGFBP‐1 and IGFBP‐3 levels in an elderly population: relation to age and sex steroid levels , 1998, Clinical endocrinology.

[27]  J. Frystyk,et al.  Circulating levels of free insulin‐like growth factors in obese subjects: the impact of Type 2 diabetes , 1999, Diabetes/metabolism research and reviews.